FDA panel backs drug from firm to be acquired by Genzyme
28028
Genzyme Corp.&#39;s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug
99180
THE REGION Cambridge biotech company Dyax Corp. has agreed to end its deal with Genzyme Corp. to codevelop a drug for the rare swelling disorder hereditary angioedema. The firms were jointly testing DX-88, a small protein considered Dyax's most important potential drug. Dyax said it will receive all the assets of the joint development deal and $17 million cash. Genzyme ...
226044
U.S. health officials said on Friday  they would review whether to take regulatory action over Merck  & Co Inc  and Schering-Plough's  cholesterol  medicine Vytorin following the drug's failure to work better  than a generic drug in a study of plaque build-up in neck  arteries.
575144
A U.S. Senate panel voted on Wednesday to set a path for generic drugmakers to seek approval of cheaper, copycat versions of expensive biotechnology medicines.
688289
The Food and Drug Administration approved Clolar, Genzyme Corp.'s new drug for patients under 21 with acute lymphocytic leukemia. An advisory panel on Dec. 1 recommended the drug be approved. Clolar was developed by Ilex Oncology Inc., the Texas firm Cambridge-based Genzyme acquired last week in a $1 billion stock transaction. The FDA panel recommended that more studies be done ...
761481
Provenge supporters weigh in on an FDA decision.
160780
Roche Holding, the world&#39;s biggest maker of diagnostic tests, has received Food and Drug Administration approval to market the first laboratory gene test that can help doctors reduce the risk of side effects for certain medications.
713941
GlaxoSmithKline Plc  has bought global rights to Danish biotech company Genmab's  most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday.
226791
A court ruling upholding the  patent on blockbuster blood-thinning drug Plavix has reignited  talk France&#39;s Sanofi-Aventis  will bid for its smaller  U.S. partner Bristol-Myers Squibb Co. .
317406
In an unusual hostile takeover attempt, Genzyme Corp. yesterday went public with a $380 million cash offer to buy a Canadian drug-development company whose board of directors has twice rejected the bid.
618409
In a surprise attempt by a Cambridge biotechnology company to trump a takeover bid by one of its neighbors, Millennium Pharmaceuticals Inc. yesterday said it had reached a $515 million deal to buy a small Canadian drug firm that Genzyme Corp. has been trying to buy since late last month.
170831
GlaxoSmithKline Plc  has bought  global rights to Danish biotech company Genmab's  most  promising new drug, a treatment for leukemia, in a record deal  worth up to $2.1 billion, the two firms said on Tuesday.
507775
By Tricia Bishop, The Baltimore Sun  Dec. 14--One of MedImmune Inc.'s major shareholders is urging the state's flagship biotech to put itself up for sale, suggesting management hasn't made the most from its assets, which include four products on the market and about 40 in the pipeline.
143377
The Food and Drug Administration (FDA) today cleared for marketing the first laboratory test system that will allow physicians to consider unique genetic information from patients in selecting medications and doses of medications for a wide variety of
56545
Piper Jaffray maintained an &quot;outperform&quot; rating and $70 target price on Genzyme (nasdaq: GENZ - news - people ), citing the FDA&#39;s approval of Clolar for the treatment of pediatric acute lymphocytic leukemia (ALL) in patients between 1 and 21 years who
424285
A federal advisory panel has backed Eli Lilly & Companyâs proposed long-acting form of its schizophrenia drug Zyprexa.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.